Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fosun Pharma

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

- PMLiVE

Health on instalment

Can US-style financial engineering underwrite ultra-expensive gene therapies?

- PMLiVE

Seattle Genetics claims key US approval for Adcetris

Becomes the first new treatment for advanced Hl in more than 40 years

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

Gilead Sciences

Gilead signs $3bn-plus gene-editing deal with Sangamo

Will use the platform for new cell-based cancer therapies

- PMLiVE

A catalyst for change

China’s plan to boost innovation and improve drug accessibility

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

- PMLiVE

Gilead adds to CAR-T assets with Cell Design Labs buyout

Gains full control of the biotherapeutics firm following its acquisition of Kite Pharma

AstraZeneca AZ

AZ pushes harder into China with new joint venture

The Anglo-Swedish group creates a new pharmaceutical business with the Chinese FIIF

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links